How can one specialist’s deep therapeutic expertise transform the way 90+ sites worldwide operate and engage patients? In the past month, Nadege Gunn, MD, CPI, gave an insightful internal presentation on MASH. A renowned expert in gastroenterology and hepatology, Dr. Gunn shared her invaluable … Read more
About half of Principal Investigators (PIs) conduct only a single study in their career. This high turnover rate results in significant inefficiencies for Sponsors and CROs, particularly when it comes to finding reliable PIs capable of delivering high-quality trial conduct and enrollment in specialized research … Read more
Velocity is proud to be a part of IQVIA’s Prime and Partner Site Programme. IQVIA have created a joint innovation group with representatives from their elite network of Prime and Super Partner sites across Europe, known as the “IQVIA Connected Research Community”. The purpose is … Read more
To bring equitable products to market, clinical trials need proportionate representation. Reaching the right patients must be prioritized at the site level, where clinical research is most visible in communities. Therefore, Velocity is heavily invested in leveraging the power of local influence to drive … Read more
Julio Rosenstock, MD, FACE, is an author of an article published yesterday in Cardiovascular Diabetology. Using baseline characteristics of study participants from an ongoing trial, researchers identified clinical characteristics of individuals with type 2 diabetes and features of stage B heart failure that may help … Read more
As Nicholas Campbell explains, good business can also be good for the environment. As Velocity improves lives by accelerating the development of new therapies, we can also build a healthier tomorrow by conducting trials in a sustainable way. How can Velocity deliver more efficient trials? Enhanced … Read more
Julio Rosenstock, MD, FACE, is the lead author of an article published today in the Oxford University Press’ Endocrine Reviews Journal. Reviewing data from Phase 2 clinical trials for basal insulins icodec and efsitora, as well as the Phase 3 icodec program, the article indicates that … Read more
Paul Evans, President and CEO and Nadege Gunn, MD, CPI, Medical Director and Senior Scientific Advisor for Velocity are highlighted in a recent article by the ACRP, The Year Ahead in Trends, Challenges, and Opportunities for Clinical Trial Sites. In the article, Dr. Gunn … Read more
Watch Christy Godwin and Laura Falcone discuss Velocity’s unique ‘Demand and Delivery’ approach. Christy and Laura work in unison to ensure full alignment among what Sponsors and CROs demand, and the quality, performance, and patient experiences Velocity delivers. In this video, they delve into: … Read more
Velocity Clinical Research, the leading multi-specialty clinical sites business, has launched its VISION technology platform to transform the way patients access and participate in clinical trials. Velocity’s VISION technology unifies patient experience and recruitment capabilities across nearly 100 locations globally. The AI-driven platform includes … Read more
A staggering 80% of clinical trials are delayed or shut down due to enrollment challenges, with half of those delays occurring at the site level. Two-thirds of principal investigators leave research after conducting a single trial. It’s time for a change. Watch Paul Evans, … Read more
Velocity Clinical Research, the leading multi-specialty clinical sites organization, today announces its further expansion in Europe, adding five sites in Poland after acquiring multi-site network KO-MED Centra Kliniczne and two in Germany, having acquired The Pulmonary Research Institute at the LungenClinic Grosshansdorf and KLB … Read more
Learn more about Velocity's capabilities
Whether you’re ready to conduct a single-site study or a complex, high-volume trial, Velocity will ensure you have the right investigators, clinical staff, and patients for your research program.
Join a remarkable team doing remarkable work
Velocity careers offer competitive pay and benefits, and reward high performance with excellent opportunities.
Whether you're an industry veteran or are looking to take your first step into clinical research, we invite you to apply at Velocity.